Antibodies, Monoclonal, HumanizedBiological ProductsBronchiolitis Obliterans Syndrome
Dr. Vedran Radojcic, MD
NPI1538398409
- Medicare services, 2022
- 91
- Part D claims, 2021
- 31
- Publications
- 23
- Clinical trials
- 1
- Industry payments
- $11,025
- Practice address
- 50 N Medical Dr, Salt Lake City, UT 84113
- Practice phone
- Call (734) 936-9814
- Professional email
- Get professional email
- Personal email
- Get personal email
- Mobile number
- Get mobile number
Find Dr. Radojcic's professional email, personal email and mobile number
Dmand AI checks each channel through healthcare-specific waterfall enrichment. See what is on file with a free account, with practice phones, licenses and affiliations.
Dr. Vedran Radojcic is a hematologist and oncologist in Salt Lake City, Utah
Dr. Radojcic practices in Salt Lake City, Utah.
Dr. Radojcic's NPI, 1538398409, was assigned on July 13, 2009. Dr. Radojcic holds Michigan license 4301095050.
NPI and contact details
- NPI
- 1538398409NPI Registry (opens in a new tab)
- NPI enumeration date
- July 13, 2009
- NPI status
- Active
- Practice phone
- (734) 936-9814
- Professional email
- Get email
- Personal email
- Get email
- Mobile number
- Get number
- Sex
- Male
Sources: NPPES NPI Registry (CMS); and Dmand AI Professional Profile Data
Dr. Vedran Radojcic's practice address is in Salt Lake City, Utah
Dr. Radojcic's practice address in the NPI Registry is 50 N Medical Dr, Salt Lake City, UT 84113, in Salt Lake County. The practice phone is (734) 936-9814.
- NPI Registry address50 N Medical Dr, Salt Lake City, UT 84113 · Salt Lake CountyPhone(734) 936-9814
Sources: NPPES NPI Registry (CMS); and Dmand AI Practice Data
Dmand AI tracks the EHR system at Dr. Vedran Radojcic's practice
Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Radojcic practices. Vendor and product names are available with a free account.
| Site | EHR vendor and product |
|---|---|
| Dr. Radojcic's practice | Available with a free account |
Source: Dmand AI Technology Install Data
For health IT teams
See the EHR and IT leaders at every site where Dr. Radojcic practices
Dmand AI maps EHR vendors, IT decision makers and buying committees across each health system and 6.2K+ hospitals, with verified contacts in the same login.
Dr. Vedran Radojcic is one of 88 hematologists and oncologists in Utah
Hematology and oncology is Dr. Radojcic's primary specialty in the NPI Registry, under taxonomy code 207RH0003X. Dr. Radojcic is licensed in Michigan.
Specialties and state licenses
- Hematology and oncology, MichiganPrimary
Hematologists and oncologists near Dr. Radojcic
Counts of hematologists and oncologists with a Dmand AI profile, by place and practice. Each opens the list.
Sources: NPPES NPI Registry (CMS); Dmand AI Professional Profile Data; and Dmand AI Peer Benchmarks
Dr. Vedran Radojcic billed Medicare for 91 services in 2022
CMS data shows 91 Medicare services from Dr. Radojcic across 1 procedure code in 2022. Medicare paid $7,130 for them. Every service was in a facility, such as a hospital, rather than an office.
Medicare services, 202291
Paid by Medicare$7,130
Procedure codes1
Dr. Radojcic's Medicare services by type, 2021 to 2022
- 2021
- 2022
- Office and hospital visits
- 2021: 1432022: 9136%
Dr. Radojcic compared with the Utah median for hematologists and oncologists, 2022
- Dr. Radojcic
- Utah median
- Medicare services
- 91vs 60785% below
- Part D claims
- 31vs 28689% below
Medians across 91 hematologists and oncologists in Utah with Dmand AI profiles that report each measure.
Dr. Radojcic's most billed Medicare procedure codes, 2022
CMS publishes codes billed for 11 or more Medicare patients. Each label is the code family; CPT descriptions are licensed by the AMA.
Need commercial claims for Dr. Radojcic?
Medicare shows one payer. Book a meeting to get commercial claims data for Dr. Radojcic and other hematologists and oncologists in Utah.
Sources: Medicare Physician & Other Practitioners - by Provider and Service (CMS), 2024 data; and Dmand AI Peer Benchmarks
Dr. Vedran Radojcic wrote 31 Medicare Part D claims in 2021
In 2021, Dr. Radojcic wrote 31 Medicare Part D claims. Every claim was for a generic drug. They cover 2 drugs, with $921 in total drug cost. In 2020, CMS named 112 claims across 8 drugs.
Part D claims, 202131
Drugs named by CMS2
Total drug cost$921
Dr. Radojcic's most prescribed drugs by claims, 2021
CMS names a drug when it has 11 or more claims. Share is of the claims for drugs CMS names.
Part D claims for drugs CMS names, 2020 to 2021
- 2020
- 2021
- Claims for drugs CMS names
- 2020: 1122021: 3172%
Drugs named by CMS: 2 in 2021, 8 in 2020.
Source: Medicare Part D Prescribers - by Provider and Drug (CMS), 2024 data, released May 6, 2026
For MedTech and pharma teams
Find hematologists and oncologists like Dr. Radojcic by procedure volume and prescribing
Filter 7.4M+ HCPs by Medicare procedures, Part D drugs and Open Payments history, then reach them with verified contacts in one login.
Dr. Vedran Radojcic has 23 publications on record
Dmand AI links 23 papers to Dr. Radojcic, published from 2010 to 2022. 2019 was the busiest year, with 3. The most frequent topics are Graft vs Host Disease, Transplantation, Homologous and Receptors, Notch. Dr. Radojcic has published most often in Blood. Dr. Radojcic's most frequent co-authors are Bruce Robert Blazar, MD, Jooho Chung, MD, PhD and Daniel Ricardo Couriel, MD.
Papers23
Years published2010 to 2022
Dr. Radojcic's papers by year, 2010 to 2022
Topics Dr. Radojcic writes about most
- Graft vs Host Disease
- Transplantation, Homologous
- Receptors, Notch
- Hematopoietic Stem Cell Transplantation
- Mice, Inbred BALB C
- Mice, Inbred C57BL
- Signal Transduction
- Bone Marrow Transplantation
Dr. Radojcic's most frequent co-authors
- Bruce Robert Blazar, MD5 shared papers
- Jooho Chung, MD, PhD5 shared papers
- Daniel Ricardo Couriel, MD4 shared papers
Recent publications by Dr. Radojcic
Adoptive TransferCD8-Positive T-LymphocytesInterleukin-17
Br J Haematol
Administration, OralAnilidesBiopsy
ConsensusGraft vs Host DiseaseNational Institutes of Health (U.S.)
See who Dr. Radojcic researches with
Physician Network Discovery turns co-authorship, shared hospitals and shared groups into a map of who Dr. Radojcic works with, so you can find a warm path to the right hematologists and oncologists.
Sources: PubMed (National Library of Medicine); and Dmand AI Research Linkage
Dr. Vedran Radojcic has worked on 1 clinical trial
Dmand AI links Dr. Radojcic to 1 clinical trial. Conditions studied include Fasciitis and Bronchiolitis Obliterans Syndrome.
Conditions in Dr. Radojcic's trials
- Fasciitis
- Bronchiolitis Obliterans Syndrome
Recent clinical trials with Dr. Radojcic
A Single-Arm, Open-Label, Phase I/II Study of Glasdegib for Sclerotic Chronic Graft-Vs-Host Disease (opens in a new tab)
TerminatedPhase 1/2
FasciitisBronchiolitis Obliterans SyndromeGlasdegib
Sources: Dmand AI Research Linkage; and ClinicalTrials.gov (National Library of Medicine)
Dr. Vedran Radojcic received $11,025 in industry payments from 2016 to 2025
CMS Open Payments shows 10 general payments to Dr. Radojcic from 5 drug and device companies from 2016 to 2025. Consulting fees make up the largest share, 93% of the total. Regeneron Pharmaceuticals, Inc. paid the most, $5,113.
General payments to Dr. Radojcic by program year, 2016 to 2025
General payments to Dr. Radojcic by kind, 2016 to 2025
$11Kin total
- Consulting fees$10,21393%
- Travel and lodging$5505%
- Food and beverage$2622%
Companies that paid Dr. Radojcic the most, 2016 to 2025
Share is of all general payments to this clinician.
Source: Open Payments (CMS), 2025 data, released July 7, 2026
Sources for Dr. Vedran Radojcic's profile data
| Data on this page | Source |
|---|---|
| NPI, name, sex, specialty and licenses | NPPES NPI Registry (CMS) (opens in a new tab)Dmand AI Professional Profile Data |
| Practice locations and phone | NPPES NPI Registry (CMS) (opens in a new tab)Dmand AI Practice Data |
| Medicare services and procedure codes | Medicare Physician & Other Practitioners - by Provider and Service (CMS) (opens in a new tab) |
| State medians for the same specialty | Dmand AI Peer Benchmarks |
| Part D prescribing | Medicare Part D Prescribers - by Provider and Drug (CMS) (opens in a new tab) |
| Publications, topics and co-authors | PubMed (National Library of Medicine) (opens in a new tab)Dmand AI Research Linkage |
| Clinical trials and co-investigators | Dmand AI Research LinkageClinicalTrials.gov (National Library of Medicine) (opens in a new tab) |
| Industry payments | Open Payments (CMS) (opens in a new tab) |
| EHR at each practice site | Dmand AI Technology Install Data |
| Similar physicians | Dmand AI Affiliation Data |
Data last refreshed October 2026Report an inaccuracyRemove my information
FAQ
Frequently asked questions about Dr. Vedran Radojcic
Spotted something out of date? Email hello@dmand.ai and we will check the record. Contact details live in the free trial.
What is Dr. Vedran Radojcic's NPI number?
Dr. Vedran Radojcic's NPI number is 1538398409. It was assigned on July 13, 2009, and it is active in the NPI Registry.
What kind of doctor is Dr. Vedran Radojcic?
Dr. Vedran Radojcic is a hematologist and oncologist in Salt Lake City, Utah. The primary specialty in the NPI Registry is Hematology & Oncology Physician (taxonomy code 207RH0003X).
Where does Dr. Vedran Radojcic practice?
Dr. Radojcic practices at 50 N Medical Dr, Salt Lake City, UT 84113.
What is Dr. Vedran Radojcic's office phone number?
The practice phone on file for Dr. Radojcic is (734) 936-9814.
What is Dr. Vedran Radojcic's medical license number?
Dr. Radojcic holds Michigan license 4301095050.
Does Dr. Vedran Radojcic accept Medicare?
Yes. CMS data shows Dr. Radojcic billed Medicare for 91 services in 2022.
What services does Dr. Vedran Radojcic bill to Medicare?
In 2022, Dr. Radojcic's most billed Medicare services were hospital inpatient care (99233).
What drugs does Dr. Vedran Radojcic prescribe most?
In 2021 Medicare Part D data, Dr. Radojcic's most prescribed drugs by claims were Acyclovir and Prednisone.
Has Dr. Vedran Radojcic received payments from drug or device companies?
CMS Open Payments shows $11,025 in general payments to Dr. Radojcic from 5 companies from 2016 to 2025. The largest total came from Regeneron Pharmaceuticals, Inc.
How long has Dr. Vedran Radojcic been practicing?
Dr. Radojcic's NPI was assigned in 2009.
Does Dr. Vedran Radojcic do research?
Dmand AI links 23 publications to Dr. Radojcic, published from 2010 to 2022. Dr. Radojcic has worked on 1 clinical trial.
Who does Dr. Vedran Radojcic publish with?
Dr. Radojcic's most frequent co-authors are Bruce Robert Blazar, MD (5 shared papers), Jooho Chung, MD, PhD (5 shared papers) and Daniel Ricardo Couriel, MD (4 shared papers).
Selling to hematology and oncology practices?
See hematologists and oncologists in Utah by site of care and group
Find the practices, groups and hospitals they work with, and the right people to contact at each.
- 30 days free
- Self-serve
- No credit card